23andMe Research Institute Welcomes John McLeod
23andMe Research Institute has announced a significant leadership change, appointing John McLeod as the new General Counsel and Chief Risk Officer. This move marks a pivotal moment for the institute as it transitions into a nonprofit operating structure. McLeod brings a wealth of experience from his previous role at Pfizer, where he navigated complex legal landscapes, focusing on regulatory and compliance matters.
John McLeod: A Wealth of Experience
McLeod comes to 23andMe with over 18 years of legal expertise, most notably as Chief International Counsel at Pfizer. His role there involved advising senior management on various intricate legal issues and overseeing significant litigation and compliance initiatives. His leadership extended to supporting the successful distribution of the Pfizer-BioNTech COVID-19 Vaccine to over 150 countries, showcasing his capability to manage large-scale legal operations.
A Vision for the Future
In sharing his enthusiasm for joining 23andMe, McLeod stated, "I'm honored to join 23andMe at such an important moment in this next phase as a nonprofit. I look forward to supporting the team, advancing our mission, and ensuring we continue to operate with the highest legal and ethical standards." This statement emphasizes his commitment to uphold the integrity of the organization during this transformative phase.
Global Perspective on Legal Affairs
Having worked in various international locations, McLeod brings a global perspective that will be crucial for the organization. His previous roles in London, Tokyo, and Madrid have equipped him with a unique understanding of legal systems and compliance requirements across diverse jurisdictions. His comprehensive background in handling cross-border mergers and acquisitions further enhances his fit for this role.
About 23andMe Research Institute
23andMe Research Institute is committed to democratizing access to genetic information, empowering individuals to learn about their ancestry and participate in groundbreaking research initiatives. Their mission focuses on scientific advancement to improve health outcomes and deepen the understanding of DNA, ultimately bringing people together around the shared goal of enhancing human health.
Commitment to Ethical Standards
McLeod's appointment not only strengthens the legal framework of the organization but also underscores its commitment to uphold ethical standards throughout its operations. The leadership under McLeod is expected to reinforce the focus on compliance and regulatory matters, ensuring that 23andMe remains at the forefront of innovation while maintaining accountability.
Media Contact
For more information about this appointment or to connect with 23andMe Research Institute, media can reach out to:
Catherine Afarian
Phone: 408.656.8872
Email: catherine.afarian@23andme.com
Frequently Asked Questions
Who has been appointed as General Counsel and Chief Risk Officer?
John McLeod has been appointed to this role at 23andMe Research Institute.
What is John McLeod’s experience prior to 23andMe?
Prior to joining 23andMe, McLeod was Chief International Counsel at Pfizer with extensive legal experience in managing complex global issues.
What are McLeod's main responsibilities at 23andMe?
McLeod will oversee all legal and regulatory matters as well as guide the organization through its transition to a nonprofit structure.
How does 23andMe aim to impact the world?
The organization aspires to be a significant contributor to scientific research and health improvement through a deeper understanding of genetic information.
What is the focus of 23andMe Research Institute?
23andMe focuses on empowering individuals with genetic information and participating in global health research initiatives.
